Research programme: scavenger mRNA decapping enzyme inhibitors - FSMA/Repligen

Drug Profile

Research programme: scavenger mRNA decapping enzyme inhibitors - FSMA/Repligen

Alternative Names: D 157495; Spinal muscular atrophy (SMA) programme - Repligen/Pfizer

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Families of SMA
  • Developer Families of SMA; Repligen Corporation
  • Class Quinazolines
  • Mechanism of Action Survival of motor neuron 1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Spinal muscular atrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy in USA
  • 15 Mar 2015 Repligen has patent protection for spinal muscular atrophy programme in USA (Repligen Form 10-K filed in March 2015)
  • 03 Jan 2013 Repligen's spinal muscular atrophy programme (including RG 3039 and backup compounds) sub-licensed to Pfizer worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top